Chang Gung Memorial Hospital's Pioneering Cellular Therapy
Cellular therapy has emerged as a groundbreaking approach in medical science, showing great promise in treating and preventing various diseases. At the forefront of this innovation is Chang Gung Memorial Hospital, renowned for its dedication to advancing healthcare through research and technology. Their initiatives in cellular therapy began in earnest in 2018, establishing a state-of-the-art Good Tissue Practice (GTP) laboratory. This facility houses six specialized cell processing labs that comply with stringent international cleanliness standards, enabling the hospital to conduct high-quality clinical trials on immune cells and regenerative medicine.
Innovative Techniques in Cellular Therapy
DC-CIK Immunotherapy: Harnessing the Body's Own Defenses
Dr. Wei-Chen Lee, a pivotal figure at Chang Gung Memorial Hospital, has devoted his expertise to exploring the application of autologous dendritic cells (DC) in treating liver cancer since 1998. His innovative therapy has yielded impressive outcomes, boasting a remarkable disease control rate of 70-80% with no tumor growth reported post-treatment. Recently, Dr. Lee's team is enhancing research on cancer vaccines, making strides to start treatments immediately after surgical interventions to thwart any potential cancer recurrence.
Advancements in NK Cell Therapy
In partnership with Professor John Yu at the Institute of Stem Cell and Translational Cancer Research, the hospital has developed a new three-stage "apexNK" technology that improves the production of natural killer (NK) cells. This cutting-edge approach, combined with an advanced viral transduction method, allows for the creation of CAR-NK cells, which counter the obstacles faced by traditional CAR therapies in the treatment of solid tumors. Going a step further, Director Shuen-Iu Hung has successfully completed Phase I clinical trials focusing on tumor neoantigens, signaling significant potential for treating metastatic and multidrug-resistant cancers.
CAR-T Cell Therapy: The Living Drug
Among the various cellular therapies, CAR-T (chimeric antigen receptor T-cell) therapy stands out as a revolutionary method in cancer treatment. Often referred to as a "living drug", this therapy modifies a patient's immune T-cells, empowering them to effectively target and eliminate specific cancer cells. The results have been particularly encouraging for treating acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), resulting in accelerated approval from regulatory bodies. These advancements underscore how far we have come in cancer treatment options.
Real-World Success Stories
Huahua, a 13-year-old, and Baobao, an 8-year-old, both exemplify the impact that CAR-T therapy can have on young patients. Both boys, facing complex challenges due to ALL and subsequent extramedullary relapse, were given the opportunity to benefit from CAR-T cell therapy. After careful consultation with their families, it was decided to proceed with this innovative treatment option. The results were heartening: both boys experienced minor side effects and were discharged after a two-week hospital stay, continuing their recovery with outpatient support.
The Future of Cancer Treatment
Dr. Cheng-Hsun Chiu, Vice-Superintendent at the hospital, reflects on how the landscape of cancer therapy is continually evolving. The transition from traditional therapies such as chemotherapy and radiotherapy has opened avenues for targeted therapy, bone marrow transplantation, and now sophisticated cellular therapies like DC-CIK and CAR-T. As research progresses, the potential for immune cell therapy continues to expand, offering hope for a wider range of treatment options that enhance effectiveness and improve patients' quality of life.
Frequently Asked Questions
What is cellular therapy?
Cellular therapy involves manipulating cells outside the body for re-introduction to treat diseases, significantly impacting how conditions like cancer are managed.
How does CAR-T therapy work?
CAR-T therapy modifies a patient's T-cells to enable them to target and kill specific cancer cells, representing a leap forward in cancer treatment.
What results have been achieved with DC-CIK therapy?
The DC-CIK therapy developed at Chang Gung Memorial Hospital has shown a 70-80% disease control rate with no reported tumor growth post-treatment.
Who is involved in advancing cancer treatment at the hospital?
A dedicated team including Dr. Wei-Chen Lee and Professor John Yu is working on innovative therapies to enhance cancer treatment outcomes.
What is the future outlook for cancer therapies?
The future of cancer therapies looks promising with continuous advancements, offering patients more effective treatment options and improved quality of life.
